- Home
- ABL vs RGNX Comparison
ABL vs RGNX Comparison
Compare ABL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- RGNX
- Stock Information
- Founded
- ABL 2004
- RGNX 2008
- Country
- ABL United States
- RGNX United States
- Employees
- ABL N/A
- RGNX N/A
- Industry
- ABL Investment Managers
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABL Finance
- RGNX Health Care
- Exchange
- ABL Nasdaq
- RGNX Nasdaq
- Market Cap
- ABL 521.6M
- RGNX 424.8M
- IPO Year
- ABL N/A
- RGNX 2015
- Fundamental
- Price
- ABL $4.83
- RGNX $8.70
- Analyst Decision
- ABL Strong Buy
- RGNX Strong Buy
- Analyst Count
- ABL 4
- RGNX 8
- Target Price
- ABL $13.13
- RGNX $31.75
- AVG Volume (30 Days)
- ABL 1.1M
- RGNX 788.1K
- Earning Date
- ABL 08-11-2025
- RGNX 07-31-2025
- Dividend Yield
- ABL N/A
- RGNX N/A
- EPS Growth
- ABL N/A
- RGNX N/A
- EPS
- ABL N/A
- RGNX N/A
- Revenue
- ABL $134,575,948.00
- RGNX $156,718,000.00
- Revenue This Year
- ABL $68.84
- RGNX $327.08
- Revenue Next Year
- ABL $26.84
- RGNX N/A
- P/E Ratio
- ABL N/A
- RGNX N/A
- Revenue Growth
- ABL 73.39
- RGNX 80.70
- 52 Week Low
- ABL $4.60
- RGNX $5.04
- 52 Week High
- ABL $11.86
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- ABL 31.28
- RGNX 48.91
- Support Level
- ABL $5.06
- RGNX $8.39
- Resistance Level
- ABL $5.68
- RGNX $9.27
- Average True Range (ATR)
- ABL 0.30
- RGNX 0.53
- MACD
- ABL 0.05
- RGNX 0.03
- Stochastic Oscillator
- ABL 21.32
- RGNX 59.86
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.